CONTENT

This web page has the following on the web page, "Improve the lifestyle and life span of Type II diabetes patients by providing long-term sustainable glycemic control." Our analyzers saw that the web page also said " A Beta-cell centric Triple Combination of Metformin, an Angiotensin II Receptor Type I Blocker ARB and a selective Cyclooxygenase-2 Inhibitor show promise of providing Long-Term Glycemic Control for Type II Diabetes Patients." The Website also said " Dr Ravi Kumar, October 3, 2016 Issue, CEOCFO MAGAZINE. A New Shift in the Paradigm. Right now, there a." The website's header had Chronic hyperglycemia as the most important optimized keyword. It is followed by insulin resistance, obesity, and inflammation which isn't as highly ranked as Chronic hyperglycemia. The next words arkaytherapeutics.com uses is Prediabetes Type 2 diabetes Company. ARKAY Therapeutics was included and will not be viewed by search engines.